Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.28 Insider Own0.40% Shs Outstand53.99M Perf Week8.03%
Market Cap1.63B Forward P/E- EPS next Y-2.20 Insider Trans-45.14% Shs Float50.97M Perf Month-1.92%
Income-243.50M PEG- EPS next Q-1.33 Inst Own72.20% Short Float17.99% Perf Quarter-19.88%
Sales1.30M P/S1252.15 EPS this Y-53.40% Inst Trans-7.01% Short Ratio3.79 Perf Half Y14.90%
Book/sh8.47 P/B3.56 EPS next Y57.40% ROA-82.60% Target Price62.89 Perf Year108.94%
Cash/sh7.32 P/C4.12 EPS next 5Y-0.20% ROE-113.30% 52W Range8.00 - 63.73 Perf YTD9.92%
Dividend- P/FCF- EPS past 5Y- ROI-103.00% 52W High-52.69% Beta1.73
Dividend %- Quick Ratio6.70 Sales past 5Y-46.80% Gross Margin- 52W Low276.87% ATR1.54
Employees270 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)54.23 Volatility5.28% 5.26%
OptionableYes Debt/Eq0.05 EPS Q/Q5.90% Profit Margin- Rel Volume0.92 Prev Close30.38
ShortableYes LT Debt/Eq0.02 EarningsFeb 28 AMC Payout- Avg Volume2.42M Price30.15
Recom1.90 SMA203.55% SMA50-1.26% SMA200-3.45% Volume2,199,200 Change-0.76%
Feb-22-17Reiterated Needham Buy $81 → $78
Jan-04-17Reiterated Morgan Stanley Equal-Weight $53 → $33
Dec-22-16Initiated JP Morgan Overweight $40
Dec-20-16Initiated Goldman Neutral
Dec-16-16Reiterated RBC Capital Mkts Outperform $106 → $98
Dec-14-16Reiterated Jefferies Hold $46 → $32
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Jun-07-16Upgrade Wedbush Neutral → Outperform $36
Jun-01-16Reiterated Wedbush Outperform $14 → $23
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Feb-23-17 09:39AM  [2/23] This Weeks Earnings Revisions Movers
Feb-22-17 01:52PM  The Contrary Indicators Are Piling Up +5.93%
09:30AM  Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics Accesswire
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 02:00PM  Did Gilead's new tool for speeding drug approval come at bargain-basement price? at bizjournals.com
11:03AM  Sarepta Sells Priority Review Voucher for $125M at Investopedia
10:09AM  Sarepta Leads Biotech Movers on Voucher Deal News
10:05AM  Sarepta sells FDA review voucher for $125M, but analyst questions price at bizjournals.com
07:28AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
07:00AM  Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Business Wire
Feb-17-17 02:30PM  Congressman Keating calls pricy Duchenne drug an example of 'gouging' at bizjournals.com
11:11AM  3 Biotech Stocks to Buy in February at Motley Fool
07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
07:05AM  Santhera opens Mass. office as local Duchenne ecosystem grows at bizjournals.com
Feb-16-17 09:50AM  Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl
Feb-15-17 08:31AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017 Business Wire
Feb-14-17 10:48AM  The Fed's Dilemma Is Quite Obvious
10:02AM  Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal
Feb-13-17 04:12PM  Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price at MarketWatch
Feb-10-17 12:04PM  Sarepta Muscular Dystrophy Drug Faces Competition at Investopedia -5.15%
Feb-09-17 03:51PM  FDA approves Marathon Pharma's Duchenne muscular dystrophy drug at MarketWatch
03:13PM  Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
Feb-07-17 04:12PM  Why Sarepta Therapeutics, Inc. Stock Rose 13.2% in January at Motley Fool
Feb-02-17 10:53AM  Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys at Motley Fool
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
Feb-01-17 01:28PM  Sarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay at Barrons.com -6.31%
11:55AM  Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
Jan-31-17 07:55PM  Catabasis shares plummet on Duchenne trial failure at bizjournals.com +7.21%
05:15PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-23-17 11:12AM  Keep Politics Out Of Science, Says Departing FDA Chief at Forbes
08:25AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : January 23, 2017
Jan-19-17 09:08AM  Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug at MarketWatch
08:40AM  Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
Jan-17-17 04:20PM  5 Healthcare Stocks Poised for Maximum Gains in 2017 at Motley Fool
02:56PM  FDA 101: What Does 'Orphan Drug Designation' Mean?
12:52PM  Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns
12:35PM  Bullish and Bearish Reversals in the Market
Jan-13-17 07:23PM  Cramer lists the stocks that you should take the cash and run on at CNBC
04:36PM  Surge From Bank Earnings Doesn't Last
Jan-12-17 10:12AM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : January 12, 2017
Jan-11-17 02:17PM  Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen at Insider Monkey -6.18%
12:25PM  Is This Going To Be Sarepta Therapeutics' Year? at Motley Fool
10:38AM  Sarepta Therapeutics: Reports of Its Demise Appear 'Greatly Exaggerated' at Barrons.com
09:46AM  Sarepta Muscular Dystrophy Drug Posts Solid Sales at Investopedia
09:30AM  Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs Accesswire
09:20AM  7 Stocks Making Big Moves With Unusual Volume
08:35AM  Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?
07:28AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : January 11, 2017
Jan-10-17 05:09PM  What Sarepta Therapeutics' CEO Said That Made the Stock Soar at Motley Fool +21.21%
03:30PM  Tuesdays Top Biopharma Movers
12:55PM  Sarepta gains $300M in value as Duchenne drug launch beats expectations at bizjournals.com
12:49PM  For Sarepta, Today's Good News Might Be Just The Beginning
11:54AM  Why Sarepta Therapeutics Has Soared 20% at Barrons.com
11:38AM  Sarepta Soars Following Encouraging Exondys 51 News
11:22AM  Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears at TheStreet
10:33AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
10:33AM  Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
10:20AM  Sarepta eyes a different approach to Duchenne: gene therapy at bizjournals.com
08:38AM  3 Tempting Stocks We're Avoiding at Motley Fool
08:30AM  Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Childrens Hospital for Microdystrophin Gene Therapy Program Business Wire
08:30AM  Sarepta Therapeutics Enters into License Agreement with Nationwide Childrens Hospital for Galgt2 Gene Therapy Program Business Wire
Jan-09-17 09:15AM  Biotech Industry Off to a Strong Start in 2017 Latest Reports on Sarepta Therapeutics and Momenta Pharmaceuticals Accesswire
Jan-06-17 07:20AM  Cambridge's Akashi plans clinical tests of three Duchenne drugs this year at bizjournals.com
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com
11:25AM  Sarepta Therapeutics: How Shares Could Double Despite the Hurdles at Barrons.com
07:21AM  Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified
06:21AM  What Biotech Investors Can Expect from the J.P. Morgan Healthcare Conference 2017
Jan-04-17 11:39AM  Sarepta Therapeutics: Slow Going? at Barrons.com
10:56AM  Trying to Knock Out Some Individual Trades, but it Is not Easy
Jan-03-17 08:30AM  Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-17 11:46PM  [$$] The FDAs Rigged Drug Committees at The Wall Street Journal
Dec-30-16 07:15PM  [$$] The FDA's Rigged Drug Committees at The Wall Street Journal
05:05PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:58PM  Why health insurers wont cover this $300,000-a-year rare disease drug at MarketWatch
11:15AM  3 Sleeper Biotechs That Could Bounce Back Strong in 2017
Dec-27-16 02:32PM  Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
Dec-23-16 11:42AM  Shark Bites: We Knew Today Would Be Slow, but Come On +6.18%
11:41AM  Sarepta Therapeutics: 'Rare Diseases Launches, Always Complex' at Barrons.com
Dec-22-16 05:52PM  Biotech buying opportunity?
12:47PM  2 Opposing Views On The Future Of Sarepta
11:20AM  What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
10:27AM  Sarepta Therapeutics: Poised for a Rebound? at Barrons.com
09:24AM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point
06:19AM  Coverage initiated on Sarepta Therapeutics by JP Morgan
Dec-21-16 10:36AM  Sarepta Therapeutics: An Appropriate Selloff? at Barrons.com
Dec-20-16 05:45PM  Sarepta's (SRPT) Application for DMD Drug Accepted in the EU
01:06PM  For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
10:01AM  Sarepta Therapeutics: Watch and Wait, Goldman Sachs Says at Barrons.com
Dec-19-16 05:23PM  Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51 Business Wire
09:10AM  The Best Biopharma CEOs of 2016 Are...
Dec-15-16 11:03AM  Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
Dec-14-16 04:17PM  Anthem, Humana, United Push Back On Sarepta's FDA-Approved DMD Drug -5.78%
02:13PM  Will Insurers Pay For Sarepta's DMD Drug? at Barrons.com
12:51PM  FDA's Woodcock speaks out about one of the agency's most controversial decisions at CNBC
07:30AM  [$$] Gormley's Take: Biotech Startups Heed Tough Lessons from a Drugmaker's Controversy at The Wall Street Journal
Dec-09-16 03:02PM  Should You Be Concerned That Smart Money Is Fleeing ALLETE Inc (ALE)? at Insider Monkey -5.31%
Dec-07-16 06:49PM  PTC Therapeutics, Inc. in 3 Charts at Motley Fool
02:46PM  Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally
04:03AM  Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT) at Insider Monkey
Dec-05-16 09:23AM  Is This Why Sarepta Therapeutics Fell 14.5% in November? at Motley Fool
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children's Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM